OverviewSuggest Edit
BridgeBio is a a clinical-stage bioteccompany focused on discovering and developing drugs for patients with grievous genetic diseases. BridgeBio has built a portfolio of transformative drug programs that address rare diseases across oncology, cardiology, dermatology, neurology and endocrinology. The drugs are in various phases of development, from pre-clinical to late-stage.
| Type | Public | |
| Founded | 2014 | |
| HQ | Palo Alto, CA, US | Map |
| Website | bridgebio.com |
Recent NewsAll News
- BridgeBio Pharma Receives FDA Fast Track Designation for Encaleret for the Treatment of Autosomal Dominant Hypocalcemia Type 1
- BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma
- BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Gene Therapy for Congenital Adrenal Hyperplasia
- BridgeBio Pharma, Inc. Reports First Quarter 2021 Financial Results And Business Update
Key People/Management at BridgeBio
Neil Kumar
Chief Executive Officer, Director
Charles Homcy
Chairman of Pharmaceuticals, Lead Director
Uma Sinha
Chief Scientific Officer
Brian C. Stephenson
Chief Financial Officer
Richard Scheller
Chairman of Research & Development, Director
Eric Aguiar
Director
BridgeBio Office Locations
BridgeBio has an office in Palo Alto
Palo Alto, CA, US (HQ)
421 Kipling St
BridgeBio Financials and Metrics
BridgeBio Revenue
BridgeBio's revenue was reported to be $8.25 m in FY, 2020
| USD | |
|---|---|
Revenue (Q1, 2021) | 462.0k |
Net income (Q1, 2021) | (171.1m) |
EBIT (Q1, 2021) | (167.5m) |
Market capitalization (4-Jun-2021) | 8.6b |
Closing stock price (4-Jun-2021) | 58.0 |
Cash (31-Mar-2021) | 471.2m |
EV | 8.3b |
BridgeBio's current market capitalization is $8.6 b.
Annual
Annual
Annual
| USD | FY, 2017 |
|---|---|
Financial Leverage | -1.7 x |
BridgeBio Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Adrenas Therapeutics, Inc. | ||
| Aspa Therapeutics, Inc. | ||
| BridgeBio Services, Inc. | ||
| Calcilytix Therapeutics, Inc. | ||
| CoA Therapeutics, Inc. | ||
| Dermecular Therapeutics, Inc. | ||
| Eidos Therapeutics, Inc. | ||
| Ferro Therapeutics, Inc. | ||
| Fortify Therapeutics, Inc. | ||
| Molecular Skin Therapeutics, Inc. |
BridgeBio Cybersecurity Score
BridgeBio Environment, Social & Governance (ESG) Ratings
BridgeBio Online and Social Media Presence
BridgeBio's Trends
BridgeBio News and Updates
June 01, 2021
BridgeBio Pharma Receives FDA Fast Track Designation for Encaleret for the Treatment of Autosomal Dominant Hypocalcemia Type 1
PALO ALTO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced tha…
May 28, 2021
BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma
Pivotal study demonstrated a clinically meaningful rate of tumor shrinkage (overall response rate) and duration of response in patients with previously-treated advanced cholangiocarcinoma (CCA) harboring an FGFR2 fusion or rearrangement
May 14, 2021
BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Gene Therapy for Congenital Adrenal Hyperplasia
- Preclinical Data for Congenital Adrenal Hyperplasia and Canavan Disease Programs Shared at American Society of Gene & Cell Therapy Annual Meeting, Enabling Anticipated Clinical Trials This Year - Preclinical Data for Congenital Adrenal Hyperplasia and Canavan Disease Programs Shared at America…
May 06, 2021
BridgeBio Pharma, Inc. Reports First Quarter 2021 Financial Results And Business Update
–Received U.S. Food and Drug Administration (FDA) approval for NULIBRY™ (fosdenopterin) for injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A
April 13, 2021
BridgeBio Pharma and the University of California, San Diego Announce Collaboration to Advance Treatments for Genetically Driven Conditions
PALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO), and the University of California, San Diego (UC San Diego) today announced a partnership to translate research in genetically driven conditions into potential therapeutic applications for patients, with a …
April 13, 2021
BridgeBio Pharma, Inc. and The Lundquist Institute Collaborate to Advance Treatments for Genetically Driven Conditions and Cancers
TORRANCE, Calif. and PALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) and The Lundquist Institute for Biomedical Innovation at the Harbor-UCLA Medical Center today announced a collaboration to translate research in genetically driven diseases and cancers …
BridgeBio Blogs
December 20, 2018
Sr. Manager/Associate Director, Drug Substance Development
The post Sr. Manager/Associate Director, Drug Substance Development appeared first on BridgeBio.
December 20, 2018
Sr. Manager/Associate Director, Analytical Development
The post Sr. Manager/Associate Director, Analytical Development appeared first on BridgeBio.
December 18, 2018
Director, Formulation Development
The post Director, Formulation Development appeared first on BridgeBio.
September 17, 2018
Business Operations Manager
The post Business Operations Manager appeared first on BridgeBio.
August 24, 2018
Director/Senior Director, CMC Project Management
The post Director/Senior Director, CMC Project Management appeared first on BridgeBio.
August 21, 2018
Preclinical Associate Scientist
The post Preclinical Associate Scientist appeared first on BridgeBio.
BridgeBio Frequently Asked Questions
When was BridgeBio founded?
BridgeBio was founded in 2014.
Who are BridgeBio key executives?
BridgeBio's key executives are Neil Kumar, Charles Homcy and Uma Sinha.
How many employees does BridgeBio have?
BridgeBio has 248 employees.
What is BridgeBio revenue?
Latest BridgeBio annual revenue is $8.2 m.
What is BridgeBio revenue per employee?
Latest BridgeBio revenue per employee is $33.3 k.
Who are BridgeBio competitors?
Competitors of BridgeBio include Hartington Pharmaceutical, Biogenes and Terns Pharmaceuticals.
Where is BridgeBio headquarters?
BridgeBio headquarters is located at 421 Kipling St, Palo Alto.
Where are BridgeBio offices?
BridgeBio has an office in Palo Alto.
How many offices does BridgeBio have?
BridgeBio has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies